Corrigendum to "In vitro and preclinical assessment of an intranasal spray formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis" [Int. J. Pharm. 535 (2018) 113-119]

Affiliations

• ¹ School of Medicine, Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK.
• ² Critical Pharmaceuticals Limited, BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK.
• ³ Identity, 19 Cavendish Crescent North, The Park, Nottingham, UK.
• ⁴ Nottingham University Hospitals NHS Trust, Queen's Medical Centre, Nottingham NG7 2UH, UK.
• ⁵ Radiological Sciences, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK.
• ⁶ School of Medicine, Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK. Electronic address: richard.pearson@nottingham.ac.uk.